-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
Vistagen Therapeutics, Inc. quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from Q3 2012 to Q3 2025.
- Vistagen Therapeutics, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending September 30, 2025 was -$19.4M, a 49.9% decline year-over-year.
- Vistagen Therapeutics, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending September 30, 2025 was -$62.2M, a 57.4% decline year-over-year.
- Vistagen Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2024 was -$51.4M, a 75.1% decline from 2023.
- Vistagen Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was -$29.4M, a 50.4% increase from 2022.
- Vistagen Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$59.2M.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Growth (%)